Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 and PD-1 Inhibitors + Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
NCT06933251Phase 2Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2025
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in rectal cancer, sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Complete Response at 2 weeks and Adverse Event rate at 6 months. Started Apr 2025; status: active, not recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06933251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933251.